Regulatory T cells (Tregs), an essential component of the human immune system, are a
heterogeneous group of T lymphocytes with the ability to suppress immune responses and …

Approximately 15% of locally advanced colorectal cancers (CRC) have DNA mismatch
repair deficiency (dMMR), resulting in high microsatellite instability and a high tumour …

In patients with locally advanced cancer without distant metastases, the neoadjuvant setting
presents a platform to evaluate new drugs. For mismatch repair proficient/microsatellite …

Microsatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient)
has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an …

Background Glioblastoma is a highly aggressive brain cancer that is resistant to
conventional immunotherapy strategies. Botensilimab, an Fc-enhanced anti-CTLA-4 …

Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses
in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 …

Dramatic advances in biological discoveries, since the 1990s, have continued to reshape
the treatment paradigm of metastatic renal cell carcinoma (RCC). Von Hippel Lindau (VHL) …

Despite the success of checkpoint inhibitors there remains an unmet need for patients that
do not respond to treatment. This review delves into the latest advancements in novel …

In recent years, immune checkpoint inhibitors (ICIs) have been widely used in malignant
solid tumors with remarkable efficacy. However, in colorectal cancer (CRC), ICIs have …

Background. Glioblastoma (GB) remains a formidable challenge in neuro-oncology, with
immune checkpoint blockade (ICB) showing limited efficacy in unselected patients. We …